You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRasagiline
Accession NumberDB01367  (EXPT02758)
TypeSmall Molecule
GroupsApproved
DescriptionRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Structure
Thumb
Synonyms
(1R)-N-Propargylindan-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
RAS
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AzilectTablet1 mg/1OralPhysicians Total Care, Inc.2010-12-03Not applicableUs
AzilectTablet1.0 mgOralTeva Pharmaceutical Industries Ltd2006-09-14Not applicableCanada
AzilectTablet.5 mg/1OralTeva Neuroscience, Inc.2006-07-10Not applicableUs
AzilectTablet1 mg/1OralAphena Pharma Solutions Tennessee, Llc2006-07-10Not applicableUs
AzilectTablet1 mg/1OralTeva Neuroscience, Inc.2006-07-10Not applicableUs
AzilectTablet0.5 mgOralTeva Pharmaceutical Industries Ltd2006-09-14Not applicableCanada
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Rasagiline RatiopharmTablet1 mgOralTeva B.V.2015-01-12Not applicableEu
Teva-rasagilineTablet0.5 mgOralTeva Canada Limited2016-05-30Not applicableCanada
Teva-rasagilineTablet1 mgOralTeva Canada Limited2016-05-30Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-rasagilineTablet0.5 mgOralApotex Inc2016-01-12Not applicableCanada
Apo-rasagilineTablet1 mgOralApotex Inc2016-01-12Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Rasagiline mesylate
ThumbNot applicableDBSALT001384
Categories
UNII003N66TS6T
CAS number136236-51-6
WeightAverage: 171.2383
Monoisotopic: 171.104799421
Chemical FormulaC12H13N
InChI KeyRUOKEQAAGRXIBM-GFCCVEGCSA-N
InChI
InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
IUPAC Name
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
SMILES
C#CCN[C@@H]1CCC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Structured Indications
PharmacodynamicsRasagiline is a propargylamine and an irreversible inhibitor of monoamine oxidase (MAO). MAO, a flavin-containing enzyme, regulates the metabolic degradation of catecholamines and serotonin in the CNS and peripheral tissues. It is classified into two major molecular species, A and B, and is localized in mitochondrial membranes throughout the body in nerve terminals, brain, liver and intestinal mucosa. MAO-A is found predominantly in the GI tract and liver, and regulates the metabolic degradation of circulating catecholamines and dietary amines. MAO-B is the major form in the human brain and is responsible for the regulation of the metabolic degradation of dopamine and phenylethylamine. In ex vivo animal studies in brain, liver and intestinal tissues rasagiline was shown to be a potent,selective, and irreversible monoamine oxidase type B (MAO-B) inhibitor. At the recommended therapeutic doses, Rasagiline was also shown to be a potent and irreversible inhibitor of MAO-B in platelets. The selectivity of rasagiline for inhibiting only MAO-B (and not MAO-A) in humans and the sensitivity to tyramine during rasagiline treatment at any dose has not been sufficiently characterized to avoid restriction of dietary tyramine and amines contained in medications.
Mechanism of actionThe precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.
TargetKindPharmacological actionActionsOrganismUniProt ID
Amine oxidase [flavin-containing] BProteinyes
inhibitor
HumanP27338 details
Apoptosis regulator Bcl-2Proteinyes
activator
HumanP10415 details
Related Articles
AbsorptionRasagiline is rapidly absorbed following oral administration. The absolute bioavailability of rasagiline is about 36%.
Volume of distribution
  • 87 L
Protein bindingPlasma protein binding ranges from 88-94% with mean extent of binding of 61-63% to human albumin over the concentration range of 1-100 ng/ml.
Metabolism

Rasagiline undergoes almost complete biotransformation in the liver prior to excretion. In vitro experiments indicate that both routes of rasagiline metabolism are dependent on the cytochrome P450 (CYP) system, with CYP 1A2 being the major isoenzyme involved in rasagiline metabolism.

Route of eliminationRasagiline undergoes almost complete biotransformation in the liver prior to excretion. Glucuronide conjugation of rasagiline and its metabolites, with subsequent urinary excretion, is the major elimination pathway. After oral administration of 14C-labeled rasagiline, elimination occurred primarily via urine and secondarily via feces (62% of total dose in urine and 7% of total dose in feces over 7 days), with a total calculated recovery of 84% of the dose over a period of 38 days. Less than 1% of rasagiline was excreted as unchanged drug in urine.
Half lifeRasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.
ClearanceNot Available
ToxicitySigns and symptoms of overdosage may include, alone or in combination, any of the following: drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions, and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineRasagiline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineRasagiline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINERasagiline may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Rasagiline can be increased when it is combined with Abiraterone.Approved
AcarboseRasagiline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololRasagiline may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Acetophenazine.Approved
AlbiglutideRasagiline may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rasagiline.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Rasagiline.Approved, Illicit
AliskirenRasagiline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Rasagiline.Approved, Investigational
AlogliptinRasagiline may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololRasagiline may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Rasagiline.Approved
AmbrisentanRasagiline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Rasagiline.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Rasagiline.Approved
AmineptineRasagiline may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Rasagiline.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amisulpride.Approved, Investigational
AmitriptylineRasagiline may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineRasagiline may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Rasagiline.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amperozide.Experimental
AmphetamineRasagiline may increase the hypertensive activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Rasagiline.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Rasagiline.Approved
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Rasagiline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Rasagiline.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rasagiline.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Rasagiline.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Asenapine.Approved
AtenololRasagiline may increase the hypotensive activities of Atenolol.Approved
AtomoxetineRasagiline may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineRasagiline may increase the hypertensive activities of Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Azaperone.Vet Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rasagiline.Approved
AzithromycinThe metabolism of Rasagiline can be decreased when combined with Azithromycin.Approved
BambuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Rasagiline.Experimental
BarbitalBarbital may increase the hypotensive activities of Rasagiline.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Rasagiline.Approved
BenazeprilRasagiline may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideRasagiline may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinRasagiline may increase the hypertensive activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Benperidol.Investigational
BenzphetamineRasagiline may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilRasagiline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Rasagiline.Approved
BetaxololRasagiline may increase the hypotensive activities of Betaxolol.Approved
BethanidineRasagiline may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bezafibrate.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bifeprunox.Investigational
BimatoprostRasagiline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololRasagiline may increase the hypotensive activities of Bisoprolol.Approved
BortezomibThe metabolism of Rasagiline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanRasagiline may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumRasagiline may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Brimonidine.Approved
BrimonidineRasagiline may increase the hypotensive activities of Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Rasagiline.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Bromperidol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Rasagiline.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Rasagiline.Approved, Investigational
BupranololRasagiline may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Rasagiline.Approved, Illicit, Investigational, Vet Approved
BupropionRasagiline may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Rasagiline.Approved, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Rasagiline.Approved
CaffeineThe metabolism of Rasagiline can be decreased when combined with Caffeine.Approved
CanagliflozinRasagiline may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanRasagiline may increase the hypotensive activities of Candesartan.Approved
CandoxatrilRasagiline may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilRasagiline may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Rasagiline.Approved
CariprazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cariprazine.Approved
CaroxazoneRasagiline may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololRasagiline may increase the hypotensive activities of Carteolol.Approved
CarvedilolRasagiline may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololRasagiline may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideRasagiline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineRasagiline may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideRasagiline may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneRasagiline may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilRasagiline may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Rasagiline.Approved
CirazolineRasagiline may increase the hypertensive activities of Cirazoline.Experimental
CitalopramRasagiline may increase the serotonergic activities of Citalopram.Approved
ClemastineRasagiline may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Rasagiline.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Rasagiline.Approved, Investigational
ClomipramineRasagiline may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineRasagiline may increase the hypotensive activities of Clonidine.Approved
ClotrimazoleThe metabolism of Rasagiline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Rasagiline.Approved, Investigational
CryptenamineRasagiline may increase the hypotensive activities of Cryptenamine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Cyamemazine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Rasagiline.Approved
CyclothiazideRasagiline may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineRasagiline may increase the anticholinergic activities of Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Rasagiline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinRasagiline may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rasagiline.Investigational
DebrisoquinRasagiline may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Rasagiline can be increased when it is combined with Deferasirox.Approved, Investigational
DeserpidineRasagiline may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Rasagiline.Approved
DesipramineRasagiline may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineRasagiline may increase the serotonergic activities of Desvenlafaxine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Rasagiline.Approved, Vet Approved
DexmethylphenidateRasagiline may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineRasagiline may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanRasagiline may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxideRasagiline may increase the hypotensive activities of Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Rasagiline.Approved
DiethylpropionRasagiline may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineRasagiline may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Rasagiline.Approved
DiltiazemRasagiline may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Rasagiline.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Rasagiline.Approved
DisopyramideRasagiline may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Rasagiline.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideRasagiline may increase the hypotensive activities of Dorzolamide.Approved
DosulepinRasagiline may increase the serotonergic activities of Dosulepin.Approved
DoxapramRasagiline may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinRasagiline may increase the hypotensive activities of Doxazosin.Approved
DoxepinRasagiline may increase the serotonergic activities of Doxepin.Approved
DoxylamineRasagiline may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droperidol.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Rasagiline is combined with Droxidopa.Approved, Investigational
DulaglutideRasagiline may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineRasagiline may increase the orthostatic hypotensive activities of Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ecopipam.Investigational
EfonidipineRasagiline may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Rasagiline.Approved, Investigational
EmpagliflozinRasagiline may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilRasagiline may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatRasagiline may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Rasagiline.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineRasagiline may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Rasagiline.Approved
EpoprostenolRasagiline may increase the hypotensive activities of Epoprostenol.Approved
EprosartanRasagiline may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rasagiline.Approved
ErgotamineRasagiline may increase the hypertensive activities of Ergotamine.Approved
EscitalopramRasagiline may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineRasagiline may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Rasagiline.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Rasagiline.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Rasagiline.Approved
EtoperidoneRasagiline may increase the serotonergic activities of Etoperidone.Approved
ExenatideRasagiline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineRasagiline may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamRasagiline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Rasagiline.Approved, Illicit, Investigational, Vet Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rasagiline.Approved
FluoxetineRasagiline may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluspirilene.Approved
FluvoxamineThe serum concentration of Rasagiline can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Formoterol.Approved, Investigational
FosinoprilRasagiline may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Rasagiline.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Rasagiline.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Rasagiline.Approved, Vet Approved
GliclazideRasagiline may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideRasagiline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideRasagiline may increase the hypoglycemic activities of Glipizide.Approved
GlyburideRasagiline may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Rasagiline.Approved, Investigational
GuanabenzRasagiline may increase the hypotensive activities of Guanabenz.Approved
GuanadrelRasagiline may increase the hypotensive activities of Guanadrel.Approved
GuanethidineRasagiline may increase the hypotensive activities of Guanethidine.Approved
GuanfacineRasagiline may increase the hypotensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Rasagiline.Approved, Vet Approved
HexamethoniumRasagiline may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Rasagiline.Approved
HydracarbazineRasagiline may increase the hypertensive activities of Hydracarbazine.Approved
HydralazineRasagiline may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideRasagiline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideRasagiline may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideRasagiline may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Rasagiline.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Rasagiline.Investigational
ImipramineRasagiline may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.Approved
IndalpineRasagiline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideRasagiline may increase the hypotensive activities of Indapamide.Approved
IndenololRasagiline may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminRasagiline may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartRasagiline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirRasagiline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineRasagiline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineRasagiline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanRasagiline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproRasagiline may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozideRasagiline may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidRasagiline may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanRasagiline may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Rasagiline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Rasagiline.Approved, Vet Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rasagiline.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rasagiline.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Rasagiline.Approved, Withdrawn
IsradipineRasagiline may increase the hypotensive activities of Isradipine.Approved
KetanserinRasagiline may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rasagiline.Approved, Nutraceutical
LabetalolRasagiline may increase the hypotensive activities of Labetalol.Approved
LacidipineRasagiline may increase the hypotensive activities of Lacidipine.Approved
LanreotideRasagiline may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostRasagiline may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineRasagiline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Rasagiline.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Rasagiline.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Rasagiline.Approved
LevomilnacipranRasagiline may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinRasagiline may increase the hypertensive activities of Levonordefrin.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Rasagiline.Approved, Investigational
LidocaineThe metabolism of Rasagiline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Rasagiline is combined with Linezolid.Approved, Investigational
LiraglutideRasagiline may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineRasagiline may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilRasagiline may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Rasagiline.Approved
LithiumThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lithium.Approved
LofexidineRasagiline may increase the hypotensive activities of Lofexidine.Approved, Investigational
LorcaserinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lorcaserin.Approved
LosartanRasagiline may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Loxapine.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Rasagiline.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.Approved
MacitentanRasagiline may increase the hypotensive activities of Macitentan.Approved
ManidipineRasagiline may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Rasagiline.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rasagiline.Approved
MebanazineRasagiline may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineRasagiline may increase the hypotensive activities of Mecamylamine.Approved
MecaserminRasagiline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Melperone.Approved
MephedroneRasagiline may increase the hypertensive activities of Mephedrone.Investigational
MephentermineRasagiline may increase the hypertensive activities of Mephentermine.Approved
MequitazineRasagiline may increase the anticholinergic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Mesoridazine.Approved
MetaraminolRasagiline may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminRasagiline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methadone.Approved
MethamphetamineRasagiline may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Rasagiline.Approved
MethohexitalMethohexital may increase the hypotensive activities of Rasagiline.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methotrimeprazine.Approved
MethoxamineRasagiline may increase the hypertensive activities of Methoxamine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Rasagiline.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methyldopa.Approved
Methylene blueRasagiline may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateRasagiline may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Rasagiline.Approved
MetipranololRasagiline may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.Approved, Investigational
MetolazoneRasagiline may increase the hypotensive activities of Metolazone.Approved
MetoprololRasagiline may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineRasagiline may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe serum concentration of Rasagiline can be increased when it is combined with Mexiletine.Approved
MianserinRasagiline may increase the neurotoxic activities of Mianserin.Approved
MibefradilRasagiline may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineRasagiline may increase the hypertensive activities of Midodrine.Approved
MifepristoneRasagiline may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolRasagiline may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranRasagiline may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Rasagiline.Approved
MinoxidilRasagiline may increase the hypotensive activities of Minoxidil.Approved
MirtazapineRasagiline may increase the central neurotoxic activities of Mirtazapine.Approved
MMDARasagiline may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moclobemide.Approved
MoexiprilRasagiline may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Morphine.Approved, Investigational
MoxonidineRasagiline may increase the hypotensive activities of Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Rasagiline.Approved, Investigational
NadololRasagiline may increase the hypotensive activities of Nadolol.Approved
NaftopidilRasagiline may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Rasagiline.Approved, Investigational
NateglinideRasagiline may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololRasagiline may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneRasagiline may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Rasagiline.Approved, Investigational
NevirapineThe metabolism of Rasagiline can be decreased when combined with Nevirapine.Approved
NialamideRasagiline may increase the hypertensive activities of Nialamide.Withdrawn
NicardipineRasagiline may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Rasagiline.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Rasagiline.Approved
NiguldipineRasagiline may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineRasagiline may increase the hypotensive activities of Nilvadipine.Approved
NimodipineRasagiline may increase the hypotensive activities of Nimodipine.Approved
NisoldipineRasagiline may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineRasagiline may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Rasagiline.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rasagiline.Approved, Investigational
NitroprussideRasagiline may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineRasagiline may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineRasagiline may increase the serotonergic activities of Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rasagiline.Approved
OctamoxinRasagiline may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotideRasagiline may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olanzapine.Approved, Investigational
OlmesartanRasagiline may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Olodaterol.Approved
OmapatrilatRasagiline may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Rasagiline.Approved
OpipramolRasagiline may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Rasagiline can be decreased when it is combined with Osimertinib.Approved
OxprenololRasagiline may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Rasagiline.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rasagiline.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Rasagiline.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Rasagiline.Approved
PargylineRasagiline may increase the hypertensive activities of Pargyline.Approved
ParoxetineRasagiline may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideRasagiline may increase the hypoglycemic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololRasagiline may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineRasagiline may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
PentoliniumRasagiline may increase the hypotensive activities of Pentolinium.Approved
PerazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perazine.Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Rasagiline.Approved, Vet Approved, Withdrawn
PerindoprilRasagiline may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Perphenazine.Approved
PethidineRasagiline may increase the serotonergic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Rasagiline.Approved
PheniprazineRasagiline may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Rasagiline can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineRasagiline may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineRasagiline may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineRasagiline may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineRasagiline may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineRasagiline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Rasagiline.Approved, Illicit
PimozideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pimozide.Approved
PinacidilRasagiline may increase the hypotensive activities of Pinacidil.Withdrawn
PindololRasagiline may increase the hypotensive activities of Pindolol.Approved
PioglitazoneRasagiline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pipotiazine.Approved
PirbuterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pirbuterol.Approved
PirlindoleRasagiline may increase the hypertensive activities of Pirlindole.Approved
PivhydrazineRasagiline may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenRasagiline may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideRasagiline may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Rasagiline.Approved, Investigational
PramlintideRasagiline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinRasagiline may increase the hypotensive activities of Prazosin.Approved
PrimidoneThe metabolism of Rasagiline can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rasagiline.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Rasagiline.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Rasagiline.Approved, Investigational, Vet Approved
PropranololRasagiline may increase the hypotensive activities of Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prothipendyl.Investigational
ProtriptylineRasagiline may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Rasagiline.Investigational
PseudoephedrineRasagiline may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.Approved
QuinaprilRasagiline may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineRasagiline may increase the hypoglycemic activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Raclopride.Investigational
RamiprilRasagiline may increase the hypotensive activities of Ramipril.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Rasagiline.Approved
RemikirenRasagiline may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Remoxipride.Approved, Withdrawn
RepaglinideRasagiline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineRasagiline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Reserpine.Approved
RifampicinThe metabolism of Rasagiline can be increased when combined with Rifampicin.Approved
RilmenidineRasagiline may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatRasagiline may increase the hypotensive activities of Riociguat.Approved
RisperidoneRasagiline may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ritanserin.Investigational
RitobegronRasagiline may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Rasagiline.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Rasagiline.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ropivacaine.Approved
RosiglitazoneRasagiline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sacubitril.Approved
SafrazineRasagiline may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salmeterol.Approved
SaprisartanRasagiline may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinRasagiline may increase the hypoglycemic activities of Saxagliptin.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
SelegilineSelegiline may increase the hypertensive activities of Rasagiline.Approved, Investigational, Vet Approved
SelexipagRasagiline may increase the hypotensive activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sertindole.Approved, Withdrawn
SertralineRasagiline may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sevoflurane.Approved, Vet Approved
SimeprevirThe metabolism of Rasagiline can be decreased when combined with Simeprevir.Approved
SitagliptinRasagiline may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanRasagiline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Rasagiline.Approved
SpiraprilRasagiline may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Rasagiline.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Rasagiline is combined with Streptokinase.Approved
SufentanilSufentanil may increase the serotonergic activities of Rasagiline.Approved, Investigational
SulfadiazineRasagiline may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleRasagiline may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleRasagiline may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sulpiride.Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Rasagiline.Approved, Investigational
SunitinibRasagiline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Rasagiline.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Rasagiline.Approved
TelmisartanRasagiline may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilRasagiline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenofovirThe metabolism of Rasagiline can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Rasagiline.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Rasagiline can be decreased when it is combined with Teriflunomide.Approved
TerlipressinRasagiline may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Rasagiline.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Rasagiline.Approved
TetryzolineRasagiline may increase the hypertensive activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Rasagiline can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Rasagiline.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thiothixene.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Rasagiline.Approved
TiaprideThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tiapride.Investigational
TiboloneRasagiline may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Rasagiline can be decreased when combined with Ticlopidine.Approved
TicrynafenRasagiline may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololRasagiline may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Rasagiline.Approved
TolazamideRasagiline may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineRasagiline may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideRasagiline may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Rasagiline.Approved, Withdrawn
ToloxatoneRasagiline may increase the hypertensive activities of Toloxatone.Approved
TorasemideRasagiline may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Rasagiline.Approved, Investigational
TrandolaprilRasagiline may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineRasagiline may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Rasagiline.Approved
TravoprostRasagiline may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trazodone.Approved, Investigational
TreprostinilRasagiline may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Rasagiline.Approved
TrichlormethiazideRasagiline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Triflupromazine.Approved, Vet Approved
TrimazosinRasagiline may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanRasagiline may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineRasagiline may increase the serotonergic activities of Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Rasagiline.Investigational
UnoprostoneRasagiline may increase the hypotensive activities of Unoprostone.Approved
ValsartanRasagiline may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Rasagiline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineRasagiline may increase the serotonergic activities of Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Rasagiline.Approved
VilanterolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Rasagiline.Approved
VinpocetineRasagiline may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Rasagiline.Approved
XylometazolineRasagiline may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineRasagiline may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ziprasidone.Approved
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Rasagiline.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol and caffeine.
References
Synthesis Reference

Jeffrey Sterling, David Lerner, Harel Rosen, Leonid Bronov, Dalia Medini-Green, Berta Iosefzon, Tirtsah Berger-Peskin, Ramy Lidor-Hadas, Eliezer Bahar, “Rasagiline formulations and processes for their preparation.” U.S. Patent US07598420, issued October 06, 2009.

US07598420
General References
  1. Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. [PubMed:20600573 ]
  2. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484 ]
  3. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186 ]
External Links
ATC CodesN04BD02
AHFS Codes
  • 28:92.00
PDB Entries
FDA labelDownload (200 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9901
Blood Brain Barrier+0.9782
Caco-2 permeable+0.5585
P-glycoprotein substrateNon-substrate0.661
P-glycoprotein inhibitor INon-inhibitor0.7409
P-glycoprotein inhibitor IINon-inhibitor0.7116
Renal organic cation transporterNon-inhibitor0.5584
CYP450 2C9 substrateNon-substrate0.8037
CYP450 2D6 substrateSubstrate0.5724
CYP450 3A4 substrateNon-substrate0.6928
CYP450 1A2 substrateInhibitor0.9037
CYP450 2C9 inhibitorNon-inhibitor0.8259
CYP450 2D6 inhibitorInhibitor0.6769
CYP450 2C19 inhibitorInhibitor0.5689
CYP450 3A4 inhibitorNon-inhibitor0.8542
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.534
Ames testNon AMES toxic0.6468
CarcinogenicityNon-carcinogens0.8959
BiodegradationNot ready biodegradable0.6073
Rat acute toxicity2.8164 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7804
hERG inhibition (predictor II)Non-inhibitor0.7137
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
TabletOral.5 mg/1
TabletOral0.5 mg
TabletOral1 mg/1
TabletOral1.0 mg
Prices
Unit descriptionCostUnit
Azilect 0.5 mg tablet12.11USD tablet
Azilect 1 mg tablet12.11USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2031714 No1998-08-252010-12-06Canada
CA2232310 No2008-01-082016-09-18Canada
US5387612 No1995-02-072012-02-07Us
US5453446 No1997-02-072017-02-07Us
US6126968 No1996-09-182016-09-18Us
US7572834 No2006-12-052026-12-05Us
US7815942 No2007-08-272027-08-27Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0249 mg/mLALOGPS
logP2.26ALOGPS
logP2.3ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)8.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.47 m3·mol-1ChemAxon
Polarizability20.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassIndanes
Sub ClassNot Available
Direct ParentIndanes
Alternative Parents
Substituents
  • Indane
  • Aralkylamine
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Naoi M, Maruyama W: Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68. [PubMed:19673610 ]
  2. Uzun M, Alp R, Uzlu E, Alp S, Citil M, Topcu B, Erdogan HM: Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):95-8. [PubMed:19499843 ]
  3. Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73. [PubMed:12043833 ]
  4. Chau KY, Cooper JM, Schapira AH: Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 2010 Nov;57(5):525-9. doi: 10.1016/j.neuint.2010.06.017. Epub 2010 Jul 17. [PubMed:20624440 ]
  5. Weinreb O, Amit T, Bar-Am O, Youdim MB: Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol. 2010 Nov;92(3):330-44. doi: 10.1016/j.pneurobio.2010.06.008. Epub 2010 Jun 19. [PubMed:20600573 ]
  6. Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9. [PubMed:15573406 ]
  7. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484 ]
  8. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
activator
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Youdim MB, Weinstock M: Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol Neurobiol. 2001 Dec;21(6):555-73. [PubMed:12043833 ]
  2. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002 Jun 28;326(2):105-8. [PubMed:12057839 ]
  3. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M: Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002 Sep-Oct;24(5):675-82. [PubMed:12200198 ]
  4. Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M: The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003 Oct 15;66(8):1635-41. [PubMed:14555244 ]
  5. Bar-Am O, Weinreb O, Amit T, Youdim MB: Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005 Nov;19(13):1899-901. Epub 2005 Sep 7. [PubMed:16148027 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P: Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag. 2007 Jun;3(3):467-74. [PubMed:18488080 ]
  2. Leegwater-Kim J, Bortan E: The role of rasagiline in the treatment of Parkinson's disease. Clin Interv Aging. 2010 May 25;5:149-56. [PubMed:20517484 ]
  3. Chen JJ, Swope DM, Dashtipour K: Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007 Sep;29(9):1825-49. [PubMed:18035186 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:45